Today’s articles on Sectors

Can You Sleep Well At Night With This REIT That Pays 6.9%? By Brad Thomas • 62 comments IBM's Decline By Andrew McElroy • 42 comments The Puzzling Excuse For Novavax's Pivotal Failure By EP Vantage • 34 comments Editors' Picks Treasuries Are Scary - Buy Apple Bonds Instead By Downtown Investment Advisory GE And Hillary Face Tough Votes By Chris DeMuth Jr. Kerrisdale Analysis On First Majestic: A Critical Review By The Critical Investor Apple: Investor Takeaways From iPhone 7 Teardowns By Mark Hibben 3 Ways To Profit From Apple - Part 2 Of 3 By Mark Bern, CFA More Editors' Picks» Basic Materials Freeport-McMoRan: A Long-Term Buy Opportunity May Have Opened Up by Orthodox Investor Teekay Tankers - Dead In The Water? by Trevor Day Occidental Petroleum Raises Its Dividend 1.3% - What Now? by Casey Hoerth Chesapeake - Icahn Sells, Should You? by Brandon Dempster Kinder Morgan: Disappointment Has A New Name by Brandon Dempster More Basic Materials» Consumer Goods Elon Musk's Nightmare Is Closer To Reality by Bill Maurer Tesla: A Critical Moment by David Deuchar Xerox Is Sort Of A No-Brainer Investment by Munger Fan Philip Morris: Time To Lock In 4% Yield? by Black Coral Research GoPro: More Than A Drone (They Said...) by Jon Quast More Consumer Goods» Financial Prospect Capital: Free Money by Christopher F. Davis At What Price Would You Double Down On Realty Income Again? by Achilles Research Ventas: Still Not A Buy After 10% Correction by Reuben Gregg Brewer Why I'm Dipping My Toe In Beaten-Down Corrections Corporation Of America by Dylan Lawrence Capital One: Cheap For A Reason? by D.M. Martins Research More Financial» Healthcare Biotech Forum Daily Digest: FDA Finally Caves On Sarepta, Biotech Rally Continues, Spotlight On Sage Therapeutics by Bret Jensen Acadia Pharmaceuticals' Nuplazid Could Become One Of The Top-Selling Psychiatric Drugs Of All Time by Bhavneesh Sharma As I Predicted, Cash-Rich Geron Optimizes Dosage In Myelofibrosis Trial by MedTechBio Long-Term Growth Looks Secure For CVS Health by Horizon Investments Avoid Concordia by Orange Peel Investments More Healthcare» Industrial Goods SolarCity Deep Dive: Solar Leases Make A Surprising Amount Of Sense For At Least 45% Of Americans by Aurelien Windenberger Vuzix Will Be The First Volume AR Player In The Enterprise. by SoundView Technology Group The No. 1 Performing Stock In California by Michael Fitzsimmons Taser: Time To Get Back In by L&F Capital Management EnPro - Hidden Unconsolidated Asset To Drive 30% Upside by Michael Boyd More Industrial Goods» Services McDonald's Follows Yum Brands, Prepares China Exit by Epoch Times A Mid-Month Look At Macau Gross Gaming Revenues by Elephant Analytics Self-Driving Carts Are The Future For Wal-Mart by ColoradoWealthManagementFund Avoid Air Lease Corporation (And The Entire Aircraft Lease Industry) by Michael Boyd The Big Comeback In Railroads by Mad Hedge Fund Trader More Services» Technology AMD: Good News Confirmed, Best Is Yet To Come by Anchorite YouTube Trying To Kill Facebook Pages by Alex Pitti The Other Side Of ZEN Blender Preview by Claudio Rizzini Intel: Can New Highs Be Sustained? by Bill Maurer Mobileye: Left In The Dust by Stone Fox Capital More Technology» Utilities Duke Energy Declines Again by Brandon Dempster More Utilities» Please do not forward this email. It allows direct access to your Seeking Alpha Portfolio. Why are you receiving this? You subscribed to Sectors at Seeking Alpha. Unsubscribe from this email or manage all your Seeking Alpha email choices here. To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders. Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017